ГоловнаArchive of numbers2017Volume 25, issue 4 (93)Disturbance of creatine kinase in motor neuron disease
Title of the article Disturbance of creatine kinase in motor neuron disease
Authors Rushkevich Iuliia
Pashkouskaya Irina
Likchachev Sergey
Year 2017 Issue Volume 25, issue 4 (93) Pages 66-72
Type of article Scientific article Index UDK 616.832.522-008.9-036.1 Index BBK -
Abstract Variety of clinical symptoms of the motor neuron disease (MND) quite often promote late detection of a disease. The search of biological markers can reveale the MND at early stages. Objective: to establish the creatine kinase (CK) activity and a number of biochemical indexes in blood in MND patients depending on a sex, age, onset and MND duration. CK, CK-MB, cholesterol, creatinine were analyzed in 249 MND (amyotrophic lateral sclerosis — ALS) patients (128 (51 %) men and 121 (49 %) woman; mean age 59 [52,5; 66] years) and 49 people of control group (24 (49 %) men and 25 (51 %) women; mean age 62 [56; 67] years) at the time of inclusion in the research. Studying of biochemical indexes was carried out on the biochemical AU 400 analyzer of Olympus with use of reagents of production Olympus. Signifi cant increase of CK activity in ALS patients is revealed (190,0 [107,0; 350,0] U/l) in comparison with control group (73,0 [53,0; 96,0] U/l (U, р = 0,000)), both men and women, the most significant at a lumbosacral onset of MND. It is established that younger age of an onset of MND and an age in which MND diagnosis was made, more long-lived course of a disease and increase in CK-MB is characteristic of ALS patients with the increased CK level. It is revealed that ALS patients with a bulbar onset were signifi cantly more senior and they had less ALS duration, than in other ALS forms. The high diagnostic sensitivity and specificity of CK were shown: in ALS men — 72 % and 100 % respectively, and a lumbosacral form of a disease the sensitivity up to 80 % significantly increases at specifi city of 100 %. The CK activity in blood in ALS men and patients with lumbosacral form ALS can be used as biomarker of diagnostics of pathological process in a skeletal musculature of extremities and assessment of ALS degree.
Key words motor neuron disease, amyotrophic lateral sclerosis, creatine kinase, cholesterol, creatinine, serum
Access to full text version of the article pdf download
Bibliography 1. Болдырев А. А. Окислительный стресс и мозг // Соросовский образовательный журнал. 2001. Т. 7, № 4. С. 221—281. 2. Евтушенко С. К., Морозова Т. М., Шестова Е. П., Евтушенко О. С. Синдром мышечной гипотонии у новорожденных и детей раннего возраста. Донецк, 2008. 240 с. 3. Завалишин И. А. Боковой амиотрофи чес кий склероз. Москва : ГЭОТАР-Медиа, 2009. 272 с. 4. Achari A., Anderson M. Myopathic changes in ALS. Pathologic analysis of muscle biopsy changes in 111 cases // Neurology. 1974. 24(5): 6477—6481. doi:10.1212/WNL.24.5.477. 5. Amato A. A., Griggs R. C. Overview of the muscular // Handb. Clin. Neurol. 2011. 101: 1—9. doi: 10.1016/B978-0-08-045031- 5.00001-3. 6. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis / Brooks B. R., Miller R. G., Swash M. & Munsat Th. L., for the World Federation of Neurology Research Group on Motor Neuron Diseases // Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 2000. Vol. 1. Issue 5. P. 293—299. doi: 10.1080/146608200300079536. 7. Relationship of creatine kinase to body composition, disease state and longevity in ALS / Gibson S., Kasarskis E., Hu N. [et al.] // Amyotroph Lateral Scler Frontotemporal Degener. 2015. 16 (7—8): 473—477. doi: 10.3109/21678421.2015.1062516. 8. Gordon P. H. Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials // Aging and Disease. 2013. 04(05): 295—310. doi.org/10.14336/ ad.2013.0400295. 9. Estimation of skeletal muscle mass, serum creatinine and creatine kinase at the onset of Amyotrophic Lateral Sclerosis / D. Ito, A. Hashizume, Y. Hijikata, [et al.] // Journal of the Neurological Sciences. 2017. Vol. 381, Supplement, P. 212. Abstract 071- WCNKioto 2017. DOI: https://doi.org/10.1016/j.jns.2017.08.606. 10. Incidence of amyotrophic lateral sclerosis in Europe / Logroscino G., Traynor B. J., Hardiman O., [et al.] // J Neurol Neurosurg. Psychiatry. 2010. 81: 385—390. doi: 10.1136/jnnp.2009.183525. 11. Can Awaji ALS criteria provide earlier diagnosis than the revised El Escorial criteria? / Okita T., Nodera H., Shibuta Y., [et al.] // J Neurol Sci. 2011; 302 (1—2): 29—32. doi: 10.1016/j.jns.2010.12.007. 12. Creatine kinase enzyme level correlatespositively with serum creatine and lean body mass, and is a prognostic Factor for survival in ALS / Rafiq M., Lee E. Bradburn M., [et al.] // Eur J. Neurol. 2016. 23(6): 1078—1078. doi: 610.1111/ene.12995. 13. Reynolds A., Laurie C., Mosley R. L., Gendelman H. E. Oxidative stress and the pathogenesis of neurodegenerative disorders // International Review of Neurobiology. 2007; 82: 297—325. doi: 10.1016/s0074-7742(07)82016-2. 14. Correlation of Creatine Kinase Levels with Clinical features and survival in Amyotrophic Lateral Sclerosis / Tai H., Cui L., Guan Y., [et al.] // Front. Neurol. 2017. 8: 322. doi: 10.3389/fneur.2017.00322.